-

KARL STORZ Announces Breakthrough Imaging Technology

IMAGE1 S™ Rubina™ Combines Multimode Fluorescence Imaging With 4K Resolution for Endosurgical Procedures

EL SEGUNDO, Calif.--(BUSINESS WIRE)--KARL STORZ Endoscopy-America, Inc., a leader in minimally invasive surgical technology and related medical systems, announces the latest advancement in endoscopic imaging. The IMAGE1 S™ Rubina™ multimode visualization system combines state-of-the-art 4K resolution with enhanced fluorescence-guided imaging using near-infrared light and indocyanine green dye (NIR/ICG). The system uses unique and proprietary dual-4K sensors and dual-LED light technology to toggle seamlessly between white-light and fluorescence modes, without the lag or mismatched frames that are common with alternative technologies. Finally, because IMAGE1 S™ is a modular system, existing 4K customers can upgrade to this technology for half the cost of competing technologies!*

IMAGE1 S™ RUBINA™ allows physicians to switch among several viewing modes to suit different surgical needs:

  • 4K Overlay – ideal for bile duct identification and visualization of other critical structures; 4K white light is combined with a 4K NIR/ICG overlay image
  • Monochromatic – ideal for perfusion; the NIR/ICG signal is presented in white on a black background, providing the clearest demarcation (used widely in a second assessment of perfusion)
  • Intensity Map – identifies intensity of the NIR/ICG signal and assigns colors based on relative response.

In addition, the new and improved RUBINA™ telescopes now offer ONE scope for every procedure, be it white light or NIR/ICG! The new design uses a proprietary glass technology that delivers edge-to-edge clarity and eliminates the need for refocusing when switching between white light and NIR modes. Exceptional image quality, improved workflow, and standardization lead to clinical, operational, and financial advantages.

Helmuth Billy, MD, a bariatric surgeon in Ventura, CA, noted, “The clinical benefits of NIR/ICG are well established. But Rubina takes it to a new level. This will of course be a great advantage in common procedures, such as the lap-chole. But more importantly, this may allow us to perform less-invasive surgeries that would’ve been thought impractical before now.”

Paul Gardner, MD, a neurosurgeon at UPMC, stated that, “The KARL STORZ IMAGE1 S Rubina endoscopic ICG fluorescence system is the gold standard for nasoseptal flap perfusion assessment in endonasal skull-base surgery. The system is also crucial for identifying critical arteries in and around tumors, from the carotid to perforators; it has helped me avoid catastrophic complications.”

Rubina is yet another game-changing technology that is a modular add-on to the IMAGE1 S™ system from KARL STORZ. “Our design philosophy is absolutely unique in that we offer our customers the ability to evolve and advance technologically by adding capability as their patient care demands it,” stated Monica Ambrose, Executive Director, Surgical Marketing. Customers can acquire what they need, when they need it, she said, whether it’s 4K ICG, 3D, flexible videoscope compatibility, etc. “This is at the core of how we strive to partner, delivering the most advanced technology at the lowest cost of ownership.”

KARL STORZ Endoscopy-America, Inc., is an affiliate of KARL STORZ SE & Co. KG, an international leader for 75 years in advanced medical technology, providing surgical and procedural imaging, instrumentation, and enterprise-wide integration. Based in Tuttlingen, Germany, KARL STORZ SE & Co. KG is a family-owned company that designs, engineers, manufactures, and markets all its products with an emphasis on visionary design, precision craftsmanship, and clinical effectiveness. For more information, call (800) 421-0837 or visit the company’s website at www.karlstorz.com.

*Based on upgrading an existing IMAGE1 S™ system

Contacts

Susan Jaffy Marx
Marketing Communications
KARL STORZ Endoscopy-America, Inc.
(424) 218-8701

KARL STORZ Endoscopy-America, Inc.


Release Versions

Contacts

Susan Jaffy Marx
Marketing Communications
KARL STORZ Endoscopy-America, Inc.
(424) 218-8701

Social Media Profiles
More News From KARL STORZ Endoscopy-America, Inc.

ADDING MULTIMEDIA KARL STORZ Announces FDA Clearance for ENDOFLATOR + Insufflator and Smoke Evacuation System

EL SEGUNDO, Calif.--(BUSINESS WIRE)--KARL STORZ, a global leader in minimally invasive surgical technology, is proud to announce it has received U.S. Food and Drug Administration (FDA) clearance for the ENDOFLATOR™ +. ENDOFLATOR + is the next-generation insufflator with integrated surgical smoke evacuation system designed to meet the evolving needs of modern operating rooms. Using carbon dioxide gas, an insufflator establishes and maintains a stable working cavity within the body during laparos...

KARL STORZ Unifies Canada, US, and Veterinary Organizations to Form North America Region Led by Sonal Matai

EL SEGUNDO, Calif.--(BUSINESS WIRE)--KARL STORZ, a family-owned medical technology company headquartered in Tuttlingen, Germany, today announced the creation of a North America region that unifies its US, Canada, and Veterinary businesses under the leadership of Sonal Matai. Matai joined KARL STORZ in 2022 and was appointed to lead KARL STORZ United States in early 2024. As President of North America, Matai will now oversee key functions such as commercial operations, research and development,...

AventaMed, a KARL STORZ Company, Receives Expanded Indication for Solo+ Tympanostomy Tube Device (TTD)

EL SEGUNDO, Calif.--(BUSINESS WIRE)--KARL STORZ United States is proud to announce that the US Food and Drug Administration (FDA) has cleared an expanded indication for the AventaMed Solo+™ Tympanostomy Tube Device (TTD), allowing its use in pediatric patients aged 6 months and older. This expanded clearance builds on the previous 510(k) clearance, which was indicated for patients 6 to 24 months old. The Solo+ device represents a significant advancement in pediatric ENT care. It is intended to...
Back to Newsroom